Harrow, Inc. (HROW) stock

HROWNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30

$30.12+1.82 (+6.43%)

Close on Nov 13, 2026Market cap $1.13BP/E –Yield –

Harrow EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Harrow's EV/EBITDA was 79.5× on Jul 31, 2026, against 197.8× a year earlier. Over the last 5 years it ranged from 17.8× to 385.9×, with a median of 92.5×.

EV/EBITDA at the end of each year

Period	Period end	Value	Change (pts)
2026	Jul 31, 2026	79.5×	+11.8
2025	Dec 31, 2025	67.7×	−242.6
2024	Apr 30, 2024	310.3×	+205.6
2023	Dec 29, 2023	104.7×	−21.8
2022	Dec 30, 2022	126.6×	+95.5
2021	Dec 31, 2021	31.1×	−256.8
2020	Dec 31, 2020	287.9×	–

Where these numbers come from

Parsed from the XBRL in Harrow's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-5 reverse split on Feb 8, 2013
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is HROW.

Compare: HROW vs OPK · HROW vs ANIP · HROW vs PHAR · HROW vs MNKD · HROW vs KMDA

Revenue growth21.3% · median 19.6%

Gross margin73.5% · median 58.8%

Operating margin-2.0% · median 5.8%

Net margin-9.4% · median -18.1%

Company	Revenue	Growth
ANIP	$1.04B	+25.9%
OPK	$501.64M	-8.3%
MNKD	$413.37M	+31.7%
HROW	$303.25M	+21.3%
KMDA	$191.85M	+13.2%
PHAR	–	–

Company

Next earnings (est.): Mar 1, 2027, after close
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 373
Held by institutions: 57.4%
Auditor: KMJ Corbin & Company LLP
SEC CIK: 1360214

Advertisement
300 × 250

See a number that looks wrong?